Dornase alfa
- Generic Name
- Dornase alfa
- Brand Names
- Pulmozyme
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 143831-71-4
- Unique Ingredient Identifier
- 953A26OA1Y
- Background
Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphool...
- Indication
Used as adjunct therapy in the treatment of cystic fibrosis.
- Associated Conditions
- Cystic Fibrosis (CF)
- Associated Therapies
- -
Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 11
- Registration Number
- NCT01356147
- Locations
- 🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Georgetown University Hospital NICU, Washington, District of Columbia, United States
RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- University Hospital, Tours
- Target Recruit Count
- 15
- Registration Number
- NCT00843817
- Locations
- 🇫🇷
University Hospital - Tours, Tours, France
A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT00680316
Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 33
- Registration Number
- NCT00671723
- Locations
- 🇺🇸
Presbyterian Hospital, Oklahoma City, Oklahoma, United States
Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 36
- Registration Number
- NCT00536952
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00434278
- Locations
- 🇺🇸
Ventura County Medical Ctr, Ventura, California, United States
🇺🇸Pulm & Critical Care Assoc, Jacksonville, Florida, United States
🇺🇸Morristown Memorial Hospital, Morristown, New Jersey, United States
Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- University of Jena
- Target Recruit Count
- 5
- Registration Number
- NCT00265434
- Locations
- 🇩🇪
Friedrich-Schiller-Universität, Jena, Thüringen, Germany
Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2006-09-14
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 540
- Registration Number
- NCT00204685
- Locations
- 🇩🇪
Charité, Universitätsmedizin Berlin, Campus Mitte, Innere Intensivstation, Berlin, Germany
🇩🇪Universität Charité, Campus Mitte, Anästhesie, Intensivstation, Berlin, Germany
🇩🇪Universitätsklinikum Erlangen Medizinische Klinik, Intensivstation I, Erlangen, Germany
Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Syntara
- Target Recruit Count
- 20
- Registration Number
- NCT00117208
- Locations
- 🇬🇧
Great Ormond Hospital for Children, London, United Kingdom
🇬🇧Royal Brompton Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.